Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
BMC Urology
Published in: BMC Urology 1/2017

Open Access 01-12-2017 | Research article

Benign prostatic enlargement can be influenced by metabolic profile: results of a multicenter prospective study

Authors: Mauro Gacci, Arcangelo Sebastianelli, Matteo Salvi, Cosimo De Nunzio, Linda Vignozzi, Giovanni Corona, Tommaso Jaeger, Tommaso Chini, Giorgio Ivan Russo, Mario Maggi, Giuseppe Morgia, Andrea Tubaro, Marco Carini, Sergio Serni

Published in: BMC Urology | Issue 1/2017

Login to get access

Abstract

Background

In last years Metabolic Syndrome (MetS) has been closely associated to Benign Prostatic Enlargement (BPE) Aim of our study is to evaluate the effect of MetS and each single MetS parameter on prostate growth in men surgically treated for BPE.

Methods

Overall, 379 men were prospectively enrolled in two tertiary referral centers. Calculated prostate volume (PV) was measured with transrectal US defining the antero-posterior (AP), the cranio-caudal (CC) and the latero-lateral (LL) diameters through the ellipsoid formula, while raw PV was calculated by suprapubic US. MetS was defined according to the NCEP-ATPIII criteria.

Results

One-hundred and forty men (36.9%) were affected by MetS. The number of MetS parameters (0 to 5) and the presence of MetS were correlated with the calculated PV. The number of MetS parameters were also directly related to increasing prostate diameters. At the binary logistic regression, MetS resulted associated to high (>60 cc) raw and calculated PV. Moreover, multivariate analysis suggested that AP diameter was mainly correlated with HDL cholesterol (r:-0.3103, p = 0.002) CC diameter with triglycerides (r:-0.191, p = 0.050) and LL diameter with systolic blood pressure (r:0.154, p = 0.044). However, at the binary logistic regression, only low HDL Cholesterol was the main determinant for the enlargement of all diameters and consequently of the whole PV.

Conclusions

Metabolic factors, specially dyslipidemia, could play a central role in the pathogenesis and progression of BPE/LUTS. Interventional studies are needed to evaluate the impact of early treatment of dyslipidemia on progression of LUTS/BPH.
Literature
1.
Berry SJ, Coffey DS, Walsh PC, Ewing LL. The development of human benign prostatic hyperplasia with age. J Urol. 1984;132:474–9.PubMed
2.
Holtgrewe HL. Economic issues and the management of benign prostatic hyperplasia. Urology. 1995;46:23–5.CrossRefPubMed
3.
Hammarsten J, Hogstedt B. Hyperinsulinaemia as a risk factor for developing benign prostatic hyperplasia. Eur Urol. 2001;39:151–8.CrossRefPubMed
4.
Vignozzi L, Rastrelli G, Corona G, Gacci M, Forti G, Maggi M. Benign prostatic hyperplasia: a new metabolic disease? J Endocrinol Invest. 2014;37(4):313–22. 
5.
Corona G, Rastrelli G, Morelli A, Vignozzi L, Mannucci E, Maggi M. Hypogonadism and metabolic syndrome. J Endocrinol Invest. 2011;34(7):557–67.PubMed
6.
De Nunzio C, Aronson W, Freedland SJ, Giovannucci E, Parsons JK. The correlation between metabolic syndrome and prostatic diseases. Eur Urol. 2012;61(3):560–70.
7.
Dahle SE, Chokkalingam AP, Gao YT, Deng J, Stanczyk FZ, Hsing AW. Body size and serum levels of insulin and leptin in relation to the risk of benign prostatic hyperplasia. J Urol. 2002;168:599–604.CrossRefPubMed
8.
Ozden C, Ozdal OL, Urgancioglu G, Koyuncu H, Gokkaya S, Memis A. The correlation between metabolic syndrome and prostatic growth in patients with benign prostatic hyperplasia. Eur Urol. 2007;51:199–203.CrossRefPubMed
9.
Gacci M, Corona G, Vignozzi L, Salvi M, Serni S, De Nunzio C, Tubaro A, Oelke M, Carini M, Maggi M. Metabolic syndrome and benign prostatic enlargement: a systematic review and meta-analysis. BJU Int. 2015;115(1):24–31.
10.
Gacci M, Bartoletti R, Figlioli S, et al. Urinary symptoms, quality of life and sexual function in patients with benign prostatic hypertrophy before and after prostatectomy: a prospective study. BJU Int. 2003;91(3):196–200.CrossRefPubMed
11.
Tubaro A, Carter S, Hind A, et al. A prospective study of the safety and efficacy of suprapubictransvesical prostatectomy in patients with benign prostatic hyperplasia. J Urol. 2001;166(1):172–6.CrossRefPubMed
12.
Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III). JAMA. 2001;285:2486–97.CrossRef
13.
Hammarsten J, Hogstedt B, Holthuis N, Mellstrom D. Components of the metabolic syndrome-risk factors for the development of benign prostatichyperplasia. Prostate Cancer Prostatic Dis. 1998;1:157–62.CrossRefPubMed
14.
15.
Rohrmann S, Smitt E, Giuvanucci E, Platz EA. Associations of obesity withlower urinary tract symptoms andnoncancer prostate surgery in the ThirdNational Health and NutritionExamination Survey. Am J Epidemiol. 2004;159:390–7.CrossRefPubMed
16.
Corona G, Gacci M, Maseroli E, Rastrelli G, Vignozzi L, Sforza A, Forti G, Mannucci E, Maggi M. Clinical correlates of enlarged prostate size in subjects with sexual dysfunction. Asian J Androl. 2014;16(5):767–73.
17.
Park YW, Min SK, Lee JH. Relationship between lower urinary tract symptoms/benign prostatic hyperplasia and metabolic syndrome in Korean Men. World J Mens Health. 2012;30(3):183–8.CrossRefPubMedPubMedCentral
18.
Fibbi B, Penna G, Morelli A, Adorini L, Maggi M. Chronic inflammation in the pathogenesis of benign prostatic hyperplasia. Int J Androl. 2010;33(3):475–88.CrossRefPubMed
19.
Lotti F, Corona G, Colpi GM, et al. Elevated body mass index correlates with higher seminal plasma interleukin 8 levels and ultrasonographic abnormalities of the prostate in men attending an andrology clinic for infertility. J Endocrinol Invest. 2011;34:e336–4263.PubMed
20.
21.
Lotti F, Corona G, Vignozzi L, et al. Metabolic syndrome and prostate abnormalities in male subjects of infertile couples. Asian J Androl. 2014;16(2):295–304.CrossRefPubMedPubMedCentral
22.
Filippi S, Vignozzi L, Morelli A, et al. Testosterone partially ameliorates metabolic profile and erectile responsiveness to PDE5 inhibitors in an animal model of male metabolic syndrome. J Sex Med. 2009;6:3274–8872.CrossRefPubMed
23.
Vignozzi L, Morelli A, Sarchielli E, et al. Testosterone protects from metabolic syndrome-associated prostate inflammation: an experimental study in rabbit. J Endocrinol. 2012;212:71–84.CrossRefPubMed
24.
Morelli A, Comeglio P, Filippi S, et al. Testosterone and farnesoid X receptor agonist INT-747 counteract high fat diet-induced bladder alterations in a rabbit model of metabolic syndrome. J Steroid Biochem Mol Biol. 2012;132:80–9249.CrossRefPubMed
25.
Vignozzi L, Gacci M, Cellai I, et al. PDE5 inhibitors blunt inflammation in human BPH: A potential mechanism of action for PDE5 inhibitors in LUTS. Prostate. 2013;73:1391–402.CrossRefPubMed
26.
Morelli A, Sarchielli E, Comeglio P, et al. Metabolic syndrome induces inflammation and impairs gonadotropin-releasing hormone neurons in the preoptic area of the hypothalamus in rabbits. Mol Cell Endocrinol. 2014;382(1):107–19.CrossRefPubMed
27.
Gacci M, Vignozzi L, Sebastianelli A, et al. Metabolic syndrome and lower urinary tract symptoms: the role of inflammation. Prostate Cancer Prostatic Dis. 2013;16:101–657.CrossRefPubMed
28.
Vignozzi L, Gacci M, Cellai I, et al. Fat boosts, while androgen receptor activation counteracts, BPH-associated prostate inflammation. Prostate. 2013;73:789–800.CrossRefPubMed
29.
St Sauver JL, Jacobsen SJ, Jacobson DJ, McGree ME, Girman CJ, Nehra A, Roger VL, Lieber MM. Statin use and decreased risk of benign prostatic enlargement and lower urinary tract symptoms. BJU Int. 2011;107(3):443–50.CrossRefPubMed
30.
Mondul AM, Giovannucci E, Platz EA. A prospective study of obesity, and the incidence and progression of lower urinary tract symptoms. J Urol. 2014;191(3):715–21.CrossRefPubMed
Metadata
Title
Benign prostatic enlargement can be influenced by metabolic profile: results of a multicenter prospective study
Authors
Mauro Gacci
Arcangelo Sebastianelli
Matteo Salvi
Cosimo De Nunzio
Linda Vignozzi
Giovanni Corona
Tommaso Jaeger
Tommaso Chini
Giorgio Ivan Russo
Mario Maggi
Giuseppe Morgia
Andrea Tubaro
Marco Carini
Sergio Serni
Publication date
01-12-2017
Publisher
BioMed Central
Published in
BMC Urology / Issue 1/2017
Electronic ISSN: 1471-2490
DOI
https://doi.org/10.1186/s12894-017-0211-9

Other articles of this Issue 1/2017

BMC Urology 1/2017 Go to the issue

Erratum

Erratum to: Expression and function of phosphodiesterases (PDEs) in the rat urinary bladder

Research article

Assessment of free-hand transperineal targeted prostate biopsy using multiparametric magnetic resonance imaging-transrectal ultrasound fusion in Chinese men with prior negative biopsy and elevated prostate-specific antigen

Case report

Infrarenal high intra-abdominal testis: fusion of T2-weighted and diffusion-weighted magnetic resonance images and pathological findings

Research article

The addition of a sagittal image fusion improves the prostate cancer detection in a sensor-based MRI /ultrasound fusion guided targeted biopsy

Research article

Efficacy of commercialised extracorporeal shock wave lithotripsy service: a review of 589 renal stones

Research article

The susceptibility to fosfomycin of Gram-negative bacteria isolates from urinary tract infection in the Czech Republic: data from a unicentric study